Introduction
============

Hemobilia causes symptoms such as upper abdominal pain, upper gastrointestinal bleeding, and jaundice, the combination of which is known as Quincke\'s triad due to bleeding in the bile duct. The main causes of hemobilia are iatrogenic and include liver biopsy or percutaneous biliary drainage. Hemobilia as a complication of plastic stent placement is exceedingly rare. To the best of our knowledge, there have only been five previously reported cases. In the present case, 2 weeks after the first plastic stent placement, the patient needed to be admitted 7 times for recurrent intermittent biliary bleeding. Several factors are associated with hemobilia after plastic stent placement. It was recently reported that endoscopic retrograde cholangiopancreatography (ERCP)-related bile duct injury, malignant tumor invasion, cholangitis, and liver abscess may contribute to hemobilia. In the present case, benign biliary stricture, recurrent cholangitis, and long-term steroid use are presumed to be the cause of hemobilia.

Case Report
===========

A 78-year-old woman was admitted for biliary stenosis and protracted cholangitis after undergoing endoscopic sphincterotomy (EST) for the treatment of biliary calculi. The patient had taken oral prednisolone for the treatment of autoimmune hepatitis for over a decade. She took oral psednisolone 30 mg/day as the initial treatment. After the usual tapering of the prednisolone to a maintenance dose of 10 mg, she received maintenance therapy for 10 years.

Her abdomen was soft and flat and no mass was palpable on physical examination. Laboratory findings revealed an elevated level of lactate dehydrogenase \[253 IU/L (normal range, 124-222 IU/L)\] and decreased level of albumin \[3.4 g/dL (normal range, 3.8-5.2 g/dL)\] ([Table 1](#t001){ref-type="table"}). ERCP and brush cytology revealed benign biliary stricture caused by recurrent cholangitis due to duodenal content reflux after EST ([Fig. 1](#g001){ref-type="fig"}, arrow). A plastic stent was placed at the left branch (B3) to prevent obstructive cholangitis without causing any injury to the bile duct.

###### 

Laboratory Data at Presentation.

                  Unit                      Unit                            Unit                           
  --------------- ------------- ----------- ------------------ ------------ ------- --------- ------------ -------
  WBC             6,340         /µL         Total bilirubin    1            g/dL    Na        146          mEq/L
  RBC             391           ×10^4^/µL   Direct bilirubin   0.2          g/dL    K         4.1          mEq/L
  Hemoglobin      12.7          g/dL        AST                22           IU/L    Cl        106          mEq/L
  Hematocrit      38.2          \%          ALT                15           IU/L    CRP       0.16         mg/dL
  Platelets       22.3          ×10^4^/µL   LDH                [253]{.ul}   IU/L    CA19-9    21           U/mL
  PT              113           \%          ALP                184          IU/L    CEA       4.6          ng/mL
  APTT            [25.6]{.ul}   sec         γ-GTP              30           IU/L    DUPAN-2   [164]{.ul}   U/mL
  Total protein   25.6          g/dL        BUN                14           mg/dL                          
  Albumin         [3.4]{.ul}    g/dL        Creatinine         0.7          mg/dL                          

Underlines show the values outside the reference ranges.

WBC: white blood cells, RBC: red blood cells, PT: prothrombin time, APTT: activated partial thromboplastin time, AST: aspartate aminotransferase, ALT: alanine aminotransferase, LDH: lactate dehydrogenase, ALP: alkaline phosphatase, γ-GTP: gamma-glutamyl transferase, BUN: blood urea nitrogen, CRP: C-reactive protein, CA19-9: carbohydrate antigen 19-9, CEA: carcinoembryonic antigen, DUPAN-2: duke pancreatic monoclonal antigen type 2

Two weeks after the procedure, the patient was readmitted with cholangitis caused by hemobilia. ERCP revealed pulsating bleeding from the bile duct. The bleeding was arrested by replacing the plastic stent ([Fig. 2](#g002){ref-type="fig"}), but the bleeding source could not be identified on subsequent angiography.

After the first bleeding, the patient needed to be admitted six times over 6 months for recurrent intermittent bleeding. However, CT, ERCP, and peroral cholangioscopy failed to establish the bleeding source. At the seventh bleeding, computed tomography (CT) revealed the extravasation of contrast dye to the bile duct ([Fig. 3A](#g003){ref-type="fig"}, arrow) and the presence of a hepatic artery aneurysm ([Fig. 3B](#g003){ref-type="fig"}, arrow). Three-dimensional CT angiography also revealed an aneurysm that developed at the side of the stent ([Fig. 4](#g004){ref-type="fig"}, arrow). The aneurysn measured about 3 mm in diameter. Angiography revealed an aneurysm at the bifurcation of segment 2 and 3 branches of the left hepatic artery ([Fig. 5](#g005){ref-type="fig"}, arrow). Successful coil embolization of the left hepatic artery pseudoaneurysm was performed. No recurrent bleeding occurred over the following days ([Fig. 6](#g006){ref-type="fig"}).

![Endoscopic retrograde cholangiopancreatography image showing biliary stricture. A plastic stent was placed to prevent obstructive cholangitis.](1349-7235-57-0049-g001){#g001}

![Endoscopic scan showing active bleeding from the duodenal papilla.](1349-7235-57-0049-g002){#g002}

![(A) Computed tomography scan during the arterial phase showing extravasation of the contrast dye to the main bile duct (white arrow) and distention of the common bile duct with hematoma formation (black arrow). (B) A hepatic artery aneurysm near the plastic stent (white arrow).](1349-7235-57-0049-g003){#g003}

![Three-dimensional computed tomography angiography image showing an aneurysm that developed adjacent to the stent.](1349-7235-57-0049-g004){#g004}

![Angiography image showing an aneurysm at the bifurcation of branches 2 and 3 of the left hepatic artery. Coil embolization of the left hepatic artery pseudoaneurysm was successfully performed.](1349-7235-57-0049-g005){#g005}

![Clinical course.](1349-7235-57-0049-g006){#g006}

Discussion
==========

Hemobilia causes symptoms, such as upper abdominal pain, upper gastrointestinal bleeding, and jaundice, the combination of which is known as Quincke\'s triad due to bleeding in the bile duct ([@B1]). The main causes of hemobilia are iatrogenic and include liver biopsy or percutaneous biliary drainage ([@B2]). Apart from iatrogenic bleeding, malignant tumor is the main cause ([@B3]). In this case, a hepatic artery pseudoaneurysm after plastic stent placement for benign biliary stricture caused the hemobilia.

Hepatic artery pseudoaneurysm as a complication of plastic stent placement for benign biliary stricture is rare. Pseudoaneurysm formation by metal stent placement for malignant biliary obstruction is reported to occur in 1.2% of cases ([@B4]). In contrast to metal stents, plastic stents seem to very rarely cause pseudoaneurysm. However, the exact prevalence remains uncertain. To the best of our knowledge, there have only been five previously reported cases of hemobilia caused by plastic stent placement ([@B5]-[@B9]). The characteristics of these five cases in addition to the case described herein are presented in [Table 2](#t002){ref-type="table"}. These cases included five women and one man 59-78 years of age. The symptoms of hemobilia appeared several weeks to several months before presentation. In almost all cases, the bleeding source was identified on CT.

###### 

Review of Case Reports on Hemobilia Caused by Plastic Stent Placement.

  No.   Reference      Age   Sex      Underlying disease                Bleeding source                                             Time to hemobilia
  ----- -------------- ----- -------- --------------------------------- ----------------------------------------------------------- -------------------
  1     5              59    female   metastasis of ovarian carcinoma   unspecified                                                 unspecified
  2     6              75    male     pancreatic pseudocysts            arteriobiliary fistula after bile duct injury               3 weeks
  3     7              62    female   Klatskin's tumor                  hepatic artery pseudoaneurysm                               2 months
  4     8              68    female   Klatskin's tumor                  hepatic artery pseudoaneurysm                               3 weeks
  5     9              75    female   cholangitis                       arteriobiliary fistula after perforation of the bile duct   5 weeks
  6     present case   78    female   benign biliary stricture          hepatic artery pseudoaneurysm                               2 weeks

Several factors are associated with hemobilia after plastic stent placement. ERCP-related bile duct injury ([@B6], [@B9]), malignant tumor invasion ([@B5], [@B8]), cholangitis ([@B7], [@B8]), and liver abscess ([@B7]) may also contribute to hemobilia. In this case, we suspect that the stent was the primary cause of the aneurysm because it developed at the same location as the stent.

However, this may not be the only cause. Recurrent cholangitis with increased intrabiliary pressure and inflammation may affect the formation of aneurysms ([@B7]). Of the 222 cases of hemobilia reported between January 1996 and December 1999, 11 cases (5%) demonstrated an etiology associated with cholangitis ([@B10]). Moreover, long-term steroid use might have also contributed to the weakness of the bile ducts. Chronic steroid use has been reported to make the arterial walls fragile ([@B11]). CT finally revealed the bleeding source after the seventh episode of hemobilia due to a slowly expanding pseudoaneurysm.

In summary, we herein reported a rare case of hepatic artery pseudoaneurysm associated with a plastic stent insertion and long-term steroid use. The aneurysm was initially difficult to detect. However, it developed after repeated bleeding. We believe that to identify the source of hemobilia, attention should be given to the possible development of a pseudoaneurysm near the plastic stent.
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